Literature DB >> 9048541

Molecular basis of HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with cyclic urea inhibitors.

P J Ala1, E E Huston, R M Klabe, D D McCabe, J L Duke, C J Rizzo, B D Korant, R J DeLoskey, P Y Lam, C N Hodge, C H Chang.   

Abstract

In cell cultures, the key residues associated with HIV-1 resistance to cyclic urea-based HIV-1 protease (PR) inhibitors are Val82 and Ile84 of HIV-1 PR. To gain an understanding of how these two residues modulate inhibitor binding, we have measured the Ki values of three recombinant mutant proteases, I84V, V82F, and V82F/I84V, for DMP323 and DMP450, and determined the three-dimensional structures of their complexes to 2.1-1.9 A resolution with R factors of 18.7-19.6%. The Ki values of these mutants increased by 25-, 0.5-, and 1000-fold compared to the wild-type values of 0.8 and 0.4 nM for DMP323 and DMP450, respectively. The wild-type and mutant complexes overall are very similar (rms deviations of 0.2-0.3 A) except for differences in the patterns of their van der Waals (vdw) interactions, which appear to modulate the Ki values of the mutants. The loss of the CD1 atom of Ile84, in the I84V mutant complexes, creates a hole in the S1 subsite, reducing the number of vdw contacts and increasing the Ki values. The V82F mutant binds DMP323 more tightly than wild type because the side chain of Phe82 forms additional vdw and edge-to-face interactions with the P1 group of DMP323. The Ki values of the single mutants are not additive because the side chain of Phe82 rotates out of the S1 subsite in the double mutant (the chi 1 angles of Phe82 and -182 in the V82F and V82F/I84V mutants differ by 90 and 185 degrees, respectively), further reducing the vdw interactions. Finally, compensatory shifts in the I84V and V82F/ I84V complexes pick up a small number of new contacts, but too few to offset the initial loss of interactions caused by the mutations. Therefore, our data suggest that variants persist in the presence of DMP323 and DMP450 because of a decrease in vdw interactions between the mutant proteases and inhibitors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9048541     DOI: 10.1021/bi962234u

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  15 in total

1.  Inhibition of the HIV-1 and HIV-2 proteases by a monoclonal antibody.

Authors:  J Lescar; J Brynda; P Rezacova; R Stouracova; M M Riottot; V Chitarra; M Fabry; M Horejsi; J Sedlacek; G A Bentley
Journal:  Protein Sci       Date:  1999-12       Impact factor: 6.725

2.  Lack of synergy for inhibitors targeting a multi-drug-resistant HIV-1 protease.

Authors:  Nancy M King; Laurence Melnick; Moses Prabu-Jeyabalan; Ellen A Nalivaika; Shiow-Shong Yang; Yun Gao; Xiaoyi Nie; Charles Zepp; Donald L Heefner; Celia A Schiffer
Journal:  Protein Sci       Date:  2002-02       Impact factor: 6.725

3.  Overcoming drug resistance in HIV-1 chemotherapy: the binding thermodynamics of Amprenavir and TMC-126 to wild-type and drug-resistant mutants of the HIV-1 protease.

Authors:  Hiroyasu Ohtaka; Adrian Velázquez-Campoy; Dong Xie; Ernesto Freire
Journal:  Protein Sci       Date:  2002-08       Impact factor: 6.725

4.  Differences in the interactions between the subunits of photosystem II dependent on D1 protein variants in the thermophilic cyanobacterium Thermosynechococcus elongatus.

Authors:  Miwa Sugiura; Eri Iwai; Hidenori Hayashi; Alain Boussac
Journal:  J Biol Chem       Date:  2010-07-14       Impact factor: 5.157

5.  Dose-response curve slope is a missing dimension in the analysis of HIV-1 drug resistance.

Authors:  Maame Efua S Sampah; Lin Shen; Benjamin L Jilek; Robert F Siliciano
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-18       Impact factor: 11.205

6.  The how and why of protein-carbohydrate interaction: a primer to the theoretical concept and a guide to application in drug design.

Authors:  H J Gabius
Journal:  Pharm Res       Date:  1998-01       Impact factor: 4.200

7.  Solvation studies of DMP323 and A76928 bound to HIV protease: analysis of water sites using grand canonical Monte Carlo simulations.

Authors:  T J Marrone; H Resat; C N Hodge; C H Chang; J A McCammon
Journal:  Protein Sci       Date:  1998-03       Impact factor: 6.725

8.  Crystal structure of an in vivo HIV-1 protease mutant in complex with saquinavir: insights into the mechanisms of drug resistance.

Authors:  L Hong; X C Zhang; J A Hartsuck; J Tang
Journal:  Protein Sci       Date:  2000-10       Impact factor: 6.725

9.  Can cyclic HIV protease inhibitors bind in a non-preferred form? An ab initio, DFT and MM-PB(GB)SA study.

Authors:  Daniel P Oehme; Robert T C Brownlee; David J D Wilson
Journal:  J Mol Model       Date:  2012-11-13       Impact factor: 1.810

10.  X-ray crystal structures of human immunodeficiency virus type 1 protease mutants complexed with atazanavir.

Authors:  Herbert E Klei; Kevin Kish; Pin-Fang M Lin; Qi Guo; Jacques Friborg; Ronald E Rose; Yaqun Zhang; Valentina Goldfarb; David R Langley; Michael Wittekind; Steven Sheriff
Journal:  J Virol       Date:  2007-05-30       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.